Biofrontera AG is a biopharmaceutical firm dedicated to the creation and marketing of pharmaceutical solutions. The company primarily targets dermatological ailments and conditions predominantly arising from sun exposure and its harmful effects on the skin. Central to its product offerings is Ameluz, a prescribed drug for addressing both localized lesions and broader areas affected by actinic keratosis. Biofrontera also supplies the BF-RhodoLED lamp, a device utilized in photodynamic therapy for the exact same lesion-directed and field-directed treatment of actinic keratosis. Additionally, its portfolio includes Belixos, an over-the-counter collection of skincare cosmetic products. Looking ahead, Biofrontera is progressing the development of Ameluz for treating field cancerization and nodular basal cell carcinoma. Its wider product range encompasses Xepi, a prescription antibiotic cream for impetigo, and Aktipak, a generic medication for acne. The company's products are available primarily in the United States, Europe, and Israel. Biofrontera AG also maintains a collaborative and partnership agreement with Maruho Co., Ltd. Established in 1997, the company's main office is located in Leverkusen, Germany.